Is Apparent Diffusion Coefficient Established as an Imaging Biomarker for Stereotactic Body Radiation Therapy Assessment in Hepatocellular Carcinoma?

Cancer J. 2023 Jul-Aug;29(4):238-242. doi: 10.1097/PPO.0000000000000668.

Abstract

In this article, as part of this special issue on biomarkers of early response, we review currently available reports regarding magnetic resonance imaging apparent diffusion coefficient (ADC) changes in hepatocellular carcinoma (HCC) in response to stereotactic body radiation therapy. We compare diffusion image acquisition, ADC analysis, methods for HCC response assessment, and statistical methods for prediction of local tumor progression by ADC metrics. We discuss the pros and cons of these studies. Following detailed analyses of existing investigations, we cannot conclude that ADC is established as an imaging biomarker for stereotactic body radiation therapy assessment in HCC.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Biomarkers
  • Carcinoma, Hepatocellular* / diagnostic imaging
  • Carcinoma, Hepatocellular* / radiotherapy
  • Diffusion Magnetic Resonance Imaging / methods
  • Humans
  • Liver Neoplasms* / diagnostic imaging
  • Liver Neoplasms* / radiotherapy
  • Magnetic Resonance Imaging
  • Retrospective Studies

Substances

  • Biomarkers